MTOR and renal cell carcinoma: Generally, systemic therapy for RCC can be categorized into three eras: cytokine therapy, target therapy (mainly targeting vascular endothelial growth factor (VEGF) or Mammalian target of rapamycin (mTOR)), and IO therapy.